Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

Analyst Ratings

Consensus Ratings for Synergy Pharmaceuticals (NASDAQ:SGYP) (?)
Ratings Breakdown: 1 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.83)
Consensus Price Target: $11.58 (183.91% upside)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Show:
DateFirmActionRatingPrice TargetActions
7/19/2016BTIG ResearchReiterated RatingBuy$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/17/2016Canaccord GenuityReiterated RatingBuy$13.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/12/2016Rodman & RenshawReiterated RatingBuy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/26/2016Roth CapitalReiterated RatingBuy$6.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/16/2016Citigroup Inc.Lower Price TargetNeutral$7.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/1/2015HC WainwrightReiterated RatingBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/18/2015Cantor FitzgeraldReiterated RatingBuy$8.50 -> $14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/12/2014Cowen and CompanyInitiated CoverageOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/14/2014AegisLower Price Target$26.00 -> $20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/30/2014 forward)

Earnings

Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.19)($0.19)($0.19)
Q2 20161($0.25)($0.25)($0.25)
Q3 20161($0.28)($0.28)($0.28)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateHeadline
07/28/16 06:40 PMRecent Analysts Ratings of Stocks: CVS Health Corporation (NYSE:CVS) , Synergy Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/28/16 06:40 PMSynergy Pharmaceuticals: Attractive Acquisition Target - Seeking Alpha
07/27/16 06:48 PMCurrent Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) PT Means ... - Review Fortune
07/26/16 09:46 AMAnalyst Recommendations On Watch List: Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Big Lots, Inc. (NYSE:BIG) - Review Fortune
07/25/16 06:31 PMSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Stock Rises ... - Review Fortune
07/23/16 10:10 AMHow Many Synergy Pharmaceuticals Inc (NASDAQ:SGYP)'s Analysts Are Bullish? - Press Telegraph
07/22/16 06:09 PMSynergy Pharmaceuticals DE (NASDAQ:SGYP) Shorted Shares Increased By 32.05% - Press Telegraph
07/22/16 09:19 AMAnalyst Rating Fluctuations to Observe: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) , Cerus Corporation ... - Street Updates
07/22/16 09:19 AMRecommendation Trends to See: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - News Oracle
07/20/16 07:18 PMHave a look at Analyst Actions: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) , Cigna Corporation (NYSE:CI) - Street Updates
07/20/16 07:18 PMSynergy Pharmaceuticals Inc Just Recorded A Sigfniciant Increase - Press Telegraph
07/20/16 07:18 PMSynergy Pharmaceuticals Inc. (SGYP) Jumps 5.52% on July 20 - Equities.com
07/19/16 06:33 PMRodman & Renshaw Analyst Remains Bullish on Synergy Pharmaceuticals Inc (SGYP); Anticipating FDA Approval for ... - Smarter Analyst
07/19/16 08:34 AMInvestor Watch: Volatility Recap on Shares of: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Engelwood Daily
07/18/16 11:59 AMHC Stocks in Hub: Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Medtronic PLC (NYSE:MDT) - share market updates (press release)
07/18/16 11:59 AMBTIG Analyst Remains Bullish On Synergy Pharmaceuticals Inc (SGYP) Despite NDA Filing Delay - Smarter Analyst
07/18/16 11:59 AMEye Catching Stock: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - News Oracle
07/18/16 11:15 AMBiotech Movers: Elite Pharmaceuticals Inc (ELTP) and Synergy Pharmaceuticals Inc (SGYP) -
07/17/16 10:27 AMShares Experiencing a Downtrend: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - TGP
07/17/16 10:27 AMSynergy Pharma (SGYP) Reaches FDA Mid-Cycle Review for Plecanatide NDA; Will Continue Enrollment in Phase 3 for IBS-C
07/17/16 09:40 AM4 Companies That Destroyed Shareholders Last Week -
07/16/16 05:48 PMShares Moving Down on the Week: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Engelwood Daily
07/16/16 05:48 PMSynergy Pharmaceuticals Sinks on FDA Update - 24/7 Wall St.
07/16/16 05:48 PMCanaccord Weighs In on Synergy Pharmaceuticals Inc (SGYP) Following Regulatory and Clinical Updates - Smarter Analyst
07/16/16 09:36 AMSynergy Pharmaceuticals Offers Update On Ongoing Irritable Bowel Syndrome With Constipation Program
07/16/16 08:48 AMSynergy Pharmaceuticals Sinks on FDA Update -
07/15/16 12:56 PMSynergy Pharmaceuticals (SGYP) Stock Slides Despite FDA Updates -
07/15/16 11:36 AMSynergy Pharmaceuticals Provides Update on Ongoing FDA Review of Plecanatide CIC NDA and IBS-C Clinical Development Program
07/15/16 11:36 AMSynergy Pharma (SGYP) Reaches Mid-Cycle Review for Plecanatide NDA; Will Continue Enrollment in Phase 3 for IBS-C - StreetInsider.com
07/14/16 06:38 PMSynergy Pharmaceuticals Inc. (SGYP) Drops 6.75% on July 13 - Equities.com
07/14/16 10:00 AMShort Term Rating on Synergy Pharmaceuticals (SGYP) - Trade Calls
07/14/16 10:00 AMEquities Trend Analysis: Key Energy Services Inc. (KEG), Synergy Pharmaceuticals, Inc. (SGYP), Waste Management ... - iStreetWire
07/14/16 10:00 AMNoticeable Buzzers: Boston Scientific Corporation (NYSE:BSX) , Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Street Updates
07/12/16 10:46 AMAnalyst's Valuable Buzzers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) , Synergy Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/12/16 10:46 AMHC Stocks Growth: Escalon Medical Corp. (NASDAQ:ESMC), Synergy Pharmaceuticals Inc (NASDAQ:SGYP) - share market updates (press release)
07/11/16 06:18 PMRodman & Renshaw Weighs In on Synergy Pharmaceuticals Inc (SGYP) Ahead of Upcoming Phase 3 Data - Smarter Analyst
07/11/16 10:59 AMStock on the Rise for the Quarter: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Engelwood Daily
07/11/16 10:59 AMOption Market: Synergy Pharmaceuticals Inc Risk Hits An Elevated Level - CML News
07/11/16 10:59 AMCompany Shares of Synergy Pharmaceuticals (NASDAQ:SGYP) Rally 6.46% - TheFounders Daily
07/11/16 10:59 AMLast Analysts Rating Review: Envision Healthcare Holdings, Inc. (NYSE:EVHC) , Synergy Pharmaceuticals, Inc ... - Street Updates
07/10/16 05:36 PMNext Weeks Broker Price Targets For Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Fiscal Standard
07/09/16 09:27 AMSynergy Pharmaceuticals Inc (NASDAQ:SGYP) Institutional Investor Sentiment Trend - Press Telegraph
07/07/16 06:28 PMMost recent Analysts Rating report: Mylan N.V. (NASDAQ:MYL) , Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Street Updates
07/06/16 11:00 AMHave a look at Analyst Actions: Insys Therapeutics, Inc. (NASDAQ:INSY) , Synergy Pharmaceuticals, Inc. (NASDAQ ... - Street Updates
07/05/16 06:03 PMHC Stocks Indications: Synergy Pharmaceuticals Inc (NASDAQ:SGYP), ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) - share market updates (press release)
07/05/16 10:48 AMThis Weeks Broker Price Targets For Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) - Fiscal Standard
07/02/16 05:54 PMSynergy Pharmaceuticals Inc on Focus After Gap Up In Today's Session - Engelwood Daily
07/01/16 09:07 AMShort Term Price Target on Synergy Pharmaceuticals (SGYP) - Trade Calls
06/30/16 09:09 AMAnalyst Rating Update on Synergy Pharmaceuticals (SGYP) - TheFounders Daily
06/28/16 06:15 PMMost recent Analysts Rating report: Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) , Alexion Pharmaceuticals, Inc ... - Street Updates

Social

About Synergy Pharmaceuticals

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGYP
  • CUSIP: 87163930
Key Metrics:
  • Previous Close: $4.11
  • 50 Day Moving Average: $3.84
  • 200 Day Moving Average: $3.51
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $733.49M
  • Beta: 689.03
  • Current Year EPS Consensus Estimate: $-0.8 EPS
  • Next Year EPS Consensus Estimate: $-0.38 EPS
Additional Links:
Synergy Pharmaceuticals (NASDAQ:SGYP) Chart for Saturday, July, 30, 2016